I. Szczygielska, D. Moroz-Ładniak, E. Zgórka
Med Sci Monit 2003; 9(2): 20-
Background: The evaluation of efficacy of interferon retreatment (6 MU,3 times a week,for 24 weeks)-the modified version. Material/Methods:The therapy with interferon was applied in 20 children (14 boys-70%and 6 girls-30%)aged 6- 16 years in whom previous interferon therapy finished at least 12 months ago.All patients were HBsAg+,HBeAg+positive, HBV DNA was indicated by PCR method and there was the increased ALAT activity from 1.5 to 10 times higher than the standard regimen.In 15 (75%)patients there had been a liver biopsy reperformed which showed the active hepaititis- grading from 8 to 14,staging from 2 to 3,the progress of the changes was observed in 10 (67%)patients. The children were treated with interferon (6MU,3 times a week,for 24 weeks)- the dose was 2-fold higher and the treatment period prolonged by 4 weeks. The results were estimated 2 years after finishing the treatment. Results: There was HBeAg/HBeAb seroconversion in 12 (60%) patients .In one child HBV DNA was negative in serum.In no child there was HBs seroconversion .In 15 (75%)patients there was a transaminases normalization of activity (including 2 patients who did not respond to HBeAg/HBeAb serocon- version retherapy),in 14 (70%)patients the normalization of transaminases lasted the whole follow-up period.In one child transaminases values elevated again after a temporary normalization of transaminases ’activity.The interferon side effects during the re-treatment were typical, with a similar intensity to those in the first therapy. Conclusions: Efficacy of repeated interferon re-tratment (6 MU, 3 times a week, for 24 weeks)seems to be higher as compared with the first IFN treatment, performed according to standard regimen accepted for children in Poland (3 MU,3 times a week ,for 20 weeks).The IRN re-treatment may be taken into consideration, especially in case of the patients for whom Lamivudine treatment is contraindicted.